InvestSMART

Integral Diagnostics Limited (ASX:IDX)

ALERT: Price-sensitive ASX Announcement for IDX
Current share price for IDX : $2.335 0.055 (2.41%)+
Announcement
Release
25 Aug 2026 9:13AM
Price at Release
$2.280
Full Release
download
Summary
Integral Diagnostics Limited reported robust financial results for the fiscal year ending June 30, 2026, with a 25.6% increase in revenue to $788.7 million and a 30.3% rise in operating EBITDA to $164.8 million. The company achieved a 20.9% operating EBITDA margin, and operating NPAT increased by 50.1% to $47.4 million. Key drivers included growth in patient volumes and Medicare indexation. The results were bolstered by strategic initiatives, such as the integration of Capitol Health and investments in network expansion and teleradiology platform IDXt. The company declared a fully franked final dividend of 6.0 cents per share, marking a 50% increase from the previous year.
Key Points
  • Revenue increased by 25.6% to $788.7 million.
  • Operating EBITDA rose by 30.3% to $164.8 million.
  • Operating NPAT surged by 50.1% to $47.4 million.
  • Operating EBITDA margin improved to 20.9%.
  • Fully franked final dividend declared at 6.0 cents per share.
  • Successful integration of Capitol Health.
  • Strong growth in patient volumes and Medicare indexation.
  • Continued expansion of IDXt teleradiology platform.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.